Bayer fronts $65M Series A for Metagenomi, a gene therapy biotech aiming to find new CRISPR enzymes
Gene editing is all the rage in biotech these days, with the field growing in prominence especially after this year’s Nobel Prize in Chemistry was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
